95374 ā
Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Sub-classes:CRYSTAL FORM OF 8-CHLORO-3-PENTYL-3,7-DIHYDRO-1H-PURIN-2,6-DIONE COMPOUND AND PREPARATION METHOD THEREFOR
#2ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF
#3PURINE COMPOUNDS FOR TREATING DISORDERS
#4SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
#5COMPOUNDS USEFUL IN PREVENTION AND/OR TREATMENT OF SENESCENT CELL-RELATED PATHOLOGIES AND DISEASES
#6An Efficient Process for the Synthesis of Methylliberine and Polymorphs Thereof
#7USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME
#8SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES
#9VASOPROTECTIVE AND CARDIOPROTECTIVE ANTIDIABETIC THERAPY
#10COCRYSTALS OF AN ADENOSINE A2B RECEPTOR ANTAGONIST
#11SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS
#12FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF
#13PURINE DIONES AS WNT PATHWAY MODULATORS
#14PURINE COMPOUNDS FOR TREATING DISORDERS
#158-SUBSTITUTED DIARYL XANTHINES AS DUAL A2A-A2B ANTAGONISTS
#16Substituted xanthines and methods of use thereof
#178-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF
#18XANTHINE CB1 INHIBITORS
#19Use of a DPP-4 inhibitor in SIRS and/or sepsis
#208-SUBSTITUTED ARYL VINYL XANTHINE DERIVATIVES AND USES THEREOF
#21ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF
#22Substituted xanthines as modulators of TRPC5 activity
#23SPECIFICALLY-SHAPED CRYSTAL OF COMPOUND AND METHOD FOR PRODUCING SAME
#24USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME
#25Polymorphs
#26SPECIFICALLY-SHAPED CRYSTAL OF COMPOUND AND METHOD FOR PRODUCING SAME
#27Small molecules for the treatment of primary cancer and cancer metastasis
#28PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO
#29Adenosine receptor antagonists and uses thereof
#30Purine diones as Wnt pathway modulators
#31Vasoprotective and cardioprotective antidiabetic therapy
#32ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF
#33Inhibiting the transient receptor potential al ion channel
#34Hyperpolarized and deuterium exchanged hyperpolarizedC and N-labeled xanthine, arginine, glutamine, and urea probes
#35Purine diones as Wnt pathway modulators
#36Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
#37Polymorphs
#38Inhibiting the transient receptor potential A1 ion channel
#39Substituted xanthines and methods of use thereof
#40Xanthine derivative inhibitors of BET proteins
#41POLYMORPHS
#42USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS
#43SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS
#44USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME
#45METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIC INJURY TO TISSUE USING THERAPEUTIC HYPOTHERMIA
#46PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO
#47Substituted xanthine derivatives
#48Substituted xanthine derivatives
#498-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
#50Substituted xanthines and methods of use thereof
#51Purine diones as Wnt pathway modulators
#52Xanthine derivative
#53Hydroxyl purine compounds and use thereof
#54Hydroxyl purine compounds and use thereof
#55Polymorphs
#56THERAPEUTIC AND/OR PROPHYLACTIC AGENT FOR LEWY BODY DISEASE
#578-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
#58Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
#59Small molecules for the treatment of primary cancer and cancer metastasis
#60VASOPROTECTIVE AND CARDIOPROTECTIVE ANTIDIABETIC THERAPY
#61Purine diones as Wnt pathway modulators
#62Kinetic resolution of racemic hydroxy ester via asymmetric catalytic hydrogenation and application thereof
#63Prevention or treatment of uratic or gouty diseases
#64Substituted xanthines and methods of use thereof
#65Inhibiting the transient receptor potential A1 ion channel
#66Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto
#67Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
#688-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
#69Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
#70Substituted xanthine derivatives
#71Polymorphs
#72Therapeutic compounds
#73Xanthine-substituted alkynyl carbamates/reverse carbamates as AB antagonists
#74Respiratory syncytial virus inhibitors
#75Process for the preparation of dipeptidylpeptidase inhibitors
#76SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
#778-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
#78Purine diones as Wnt pathway modulators
#79Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
#80Purine inhibitors of human phosphatidylinositol 3-kinase delta
#81AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN
#828-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
#83Method for preparing an important intermediate of linagliptin
#84Substituted xanthine derivatives
#85Process for the preparation of dipeptidylpeptidase inhibitors
#86Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
#87Xanthine derivative
#88PHOSPHODIESTERASE 1-TARGETING TRACERS AND METHODS
#89Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
#90Substituted fused pyrimidine compounds
#91NOVEL COMPOUNDS
#92Amorphous form of linagliptin and process for preparation thereof
#93Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
#94Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
#95METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS
#96Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
#97Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies
#988-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
#99Polymorph of linagliptin benzoate
#100Heterocyclic compounds and uses thereof in the treatment of sexual disorders
#101APOPTOSIS-INDUCING MOLECULES AND USES THEREFOR
#102Treating protein folding disorders with small molecule CFTR correctors
#103Aadenosine receptor antagonists
#104Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds
#105Inhibitors of p75 receptor and their uses
#106USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS
#107USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME
#108Hetero ring-fused imidazole derivative having AMPK activating effect
#109Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
#110Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
#111XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
#112NOVEL COMPOUNDS
#113A2B ADENOSINE RECEPTOR ANTAGONISTS
#114POLYMORPHS
#115Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
#116Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
#117Substituted fused pyrimidine compounds, its preparation and uses thereof
#118Method of inhibiting hepatic fibrosis as a result of liver replacement or repair using Aadenosine receptor antagonists
#1198-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
#120Deuterium-substituted xanthine derivatives and methods of use
#121Phosphodiesterase 1-targeting tracers and methods
#122Vasoprotective and cardioprotective antidiabetic therapy
#123Substituted fused pyrimidine compounds
#124Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
#125Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
#126A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES
#127XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS
#128Aadenosine receptor antagonists
#129Tris salts of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione
#130Method of decreasing hepatotoxic side effects using Aadenosine receptor antagonists
#131Prodrugs of Aadenosine receptor antagonists
#132Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
#133Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
#134A2B ADENOSINE RECEPTOR ANTAGONISTS
#135Inhibitor of analgesic tolerance
#136Substituted 8-[6-amino-3-pyridyl]xanthines
#137Anti-angiogenic compounds
#138Deuterium substituted xanthine derivatives
#139Substituted xanthine derivatives
#140Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function
#141SUBSTITUTED 8-HETEROARYL XANTHINES
#142A2B Adenosine Receptor Antagonists
#143Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
#144Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
#145XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS
#146Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
#1477-[4-(Benzhydrylpiperazinyl-1)butyl]-3-methylxanthine and its salts with organic or inorganic acids possessing antihistaminic and antiallergenic activity
#148Xanthine derivatives as selective HM74A agonists
#149Compounds
#150XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
#151Pyrazolyl substituted xanthines
#152XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS
#153XANTHINE MODULATORS OF ADENOSINE A1 RECEPTOR
#154Pro-drugs of A2B Adenosine Receptor Antagonists
#155Heterocyclic compounds and uses thereof in the treatment of sexual disorders
#156HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes
#157Bicyclic Compounds and Their Use
#158Heterocyclic compounds as adenosine receptor antagonist
#159ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME
#160Xanthine Derivatives with HM74A Receptor Activity
#161Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
#162Substituted 8-[6-amino-3pyridyl]xanthines
#163A2B ADENOSINE RECEPTOR ANTAGONISTS
#164Xanthine derivates, their preparation and their use in pharmaceutical compositions
#165NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION
#166Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
#167A1 Adenosine Receptor Antagonists
#168Novel Compounds 737
#169Condensed imidazole derivatives
#170Xanthine Derivatives, Processes For Preparing Them And Their Uses
#171A2B ADENOSINE RECEPTOR ANTAGONISTS
#172BENZYLATED PDE4 INHIBITORS
#1738-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
#1748-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
#1758-alkynylxanthines and derivatives
#176METHOD OF TREATING BRAIN ISCHEMIA
#177Substituted 8-heteroaryl xanthines
#178A2B ADENOSINE RECEPTOR ANTAGONISTS
#179Aadenosine receptor antagonists
#180BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS
#181A2B adenosine receptor antagonists
#182KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER
#183Xanthine phosphodiesterase V inhibitors
#184Adenosine A2B receptor antagonists
#185ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME
#186Substituted 8-[6-amino-3-pyridyl]xanthines
#187Aadenosine receptor antagonists
#188A1 Adenosine Receptor Antagonists
#189Substituted 8-aminoalkylthioxanthines, and their use as inhibitors of dipeptidyl peptidase IV
#190POLYMORPHS
#191Derivatives of 8-substituted xanthines
#192Compositions and methods for treating respiratory disorders
#193Method of treating hepatic disease using Aadenosine receptor antagonists
#194N,Nā²-substituted-1,3-diamino-2-hydroxypropane derivatives
#195Benzylated PDE4 inhibitors
#196Prophylatic and/or therapeutic agents for chronic musculoskeletal pain
#197Aralkyl ester soft drugs
#198Xanthines with HM74A receptor activity
#1995-phenylpyrimidines, their preparation, intermediates for their preparation, and their use for controlling harmful fungi
#200Agents for preventing and/or treating higher brain dysfunctions
#201Pyridyl substituted xanthines
#202Pyrazolyl substituted xanthines
#203Adenosine receptor antagonists and methods of making and using the same
#204Prodrugs of Aadenosine receptor antagonists
#205Aadenosine receptor antagonists
#206Method of treating brain ischemia
#207Adenosine receptor antagonists and methods of making and using the same
#208XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
#209Novel compounds for treatment of cancer and disorders associated with angiogenesis function
#210Method and compositions for temporarily incapacitating subjects
#211Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof
#212Microcrystal
#213Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
#2148-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
#215Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
#2168-heteroaryl xanthine adenosine Areceptor antagonists
#217Method of stabilizing diarylvinylene compound
#2188-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
#219Novel condensed imidazole derivatives
#220Purine derivatives as liver X receptor agonists
#221Condensed imidazole derivatives
#2228-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
#223Methods for the synthesis of substituted purines
#224Aadenosine receptor antagonists
#225Adenosine receptor antagonists and methods of making and using the same
#226Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities
#227Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase
#228Method of treating ischemia reperfusion injury using adenosine receptor antagonists
#2298-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
#230A1 adenosine receptor antagonists
#231Xanthine phosphodiesterase V inhibitors
#232Therapeutic agent for eating disorders
#233Bicyclic imidazole derivatives, the preparation thereof and their use as pharmaceutical compositions
#234Aadenosine receptor antagonists
#235Xanthine phosphodiesterase V inhibitors
#236Substituted 8-heteroaryl xanthines
#2378-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
#238Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
#239Aadenosine receptor antagonists
#240Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
#241Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction